New Delhi, Sept. 10 -- In a landmark medical breakthrough, Russia has developed Enteromix the world's first personalized mRNA-based cancer vaccine showing 100% efficacy in early clinical trials. Announced by the Federal Medical and Biological Agency (FMBA) and unveiled at the St. Petersburg International Economic Forum 2025, the vaccine is now awaiting final regulatory approval. If cleared, it will mark a transformative leap in precision oncology, offering tailored treatment based on each patient's unique tumor genetics.

Enteromix was developed jointly by Russia's National Medical Research Radiology Centre and the Engelhardt Institute of Molecular Biology. Unlike preventive vaccines, Enteromix is therapeutic designed for patients already...